Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
New vaccines research from Nanjing Medical University described
May 7th, 2008
According to a study from Nanjing, People's Republic of China, "The tumor-associated antigen, mucin4 (MUC4), is overexpressed on various epithelial malignancies, making it a potentially broadly applicable candidate vaccine therapy. In this paper, we report on the creation of a dendritic cell (DC)-based vaccine, using cells transduced with the universal DR-restricted Th helper epitope (PADRE) combined with human leukocyte antigen (HLA)-A1- and HLA-A2-restricted epitopes from MUC4 (rAd-pE-DCs)." "We examined this vaccine's biologic characteristics and immune activity in vitro, finding that infection with the polyepitope adenovirus did not alter the typical morphology of...
Source: Vaccine Weekly (2008-05-07)
|
